Pentwater Capital Management 13F: New $2M Stake in Medline (MDLN)

Pentwater Capital Management has opened a new position in Medline Inc. (NASDAQ: MDLN), acquiring 50,000 shares valued at approximately $1.8 million. This move, reported in a recent SEC filing, marks a fresh investment for the firm as of the reporting period ending May 15, 2026.

What Changed in Pentwater Capital Management's Medline Inc. Position

Pentwater Capital Management initiated a new stake in Medline Inc. by purchasing 50,000 shares. This strategic move reflects the firm's decision to invest approximately $1.8 million in the healthcare company, which focuses on medical instruments and supplies.

Other Institutional Activity in Medline Inc.

Several notable institutional investors have also adjusted their positions in Medline Inc. Carlyle Group Inc. reduced its holdings by 28.2 million shares, ending with 187.1 million shares valued at $8.33 billion, a 13.1% decrease. H&F Corporate Investors X, Ltd. similarly decreased its holdings by 13.1%, selling 13 million shares to hold 86.5 million shares worth $3.85 billion. On the other hand, FMR LLC increased its position by 10.2 million shares, now holding 36.6 million shares valued at $1.63 billion, marking a 38.7% increase. Capital Research Global Investors and Invesco Ltd. also boosted their holdings significantly, with Invesco Ltd. showing a remarkable 728.8% increase.

Medline Inc. Stock Up 24.7%

Shares of Medline Inc. traded near $36.05 on Thursday. The company boasts a market cap of $29.35 billion and a P/E ratio of 30.45, with a forward P/E of 20.81. Medline's stock has seen a 52-week range from $32.82 to $50.88. The company's 50-day moving average is $40.34, while its 200-day moving average is $42.48. Medline maintains a strong liquidity position with a current ratio of 4.41 and a quick ratio of 2.34, though it carries a debt-to-equity ratio of 65.31.

Recent Earnings

Medline Inc. reported revenue of $29.14 billion with a growth rate of 10.7%. The company's net margin stood at 3.3%, and it achieved a return on equity of 6.05%. Earnings per share came in at $1.14. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at Medline Inc.

On June 16, 2026, Douglas Golwas, Chief Commercial Officer, sold 100,000 shares under a planned sale at an average price of $36.77. Amanda Laabs, Chief Product Officer, and Stephen Miller, Chief Operating Officer, each sold 1,889 shares at a price of $36.61 on June 15, 2026.

Analysts Set New Price Targets

On June 3, 2026, Baird maintained a 'buy' rating on Medline Inc. with a $45 price target. Similarly, Barclays maintained its 'buy' rating with the same target. BNP Paribas kept a 'hold' rating with a $40 target on May 14, 2026. The consensus among 27 analysts is a 'buy' rating, with a mean target price of $51.15.

About Medline Inc.

Medline Inc., headquartered in Northfield, Illinois, is a leading manufacturer and distributor of medical supplies and equipment. The company operates through its Medline Brand and Supply Chain Solutions segments, providing a wide range of products from surgical solutions to lab diagnostics. Founded in 1966, Medline serves healthcare facilities across the globe and employs approximately 45,000 people under the leadership of CEO James M. Boyle.

Bottom Line

Pentwater Capital Management's new position in Medline Inc. highlights the firm's interest in the healthcare sector. Investors often track such institutional moves for insights into potential growth areas. It's important to remember that 13F filings reflect holdings at the end of the quarter and may not represent current positions.